CN112955449B - 制备bet溴结构域抑制剂的固体形式的方法 - Google Patents

制备bet溴结构域抑制剂的固体形式的方法 Download PDF

Info

Publication number
CN112955449B
CN112955449B CN201980060128.8A CN201980060128A CN112955449B CN 112955449 B CN112955449 B CN 112955449B CN 201980060128 A CN201980060128 A CN 201980060128A CN 112955449 B CN112955449 B CN 112955449B
Authority
CN
China
Prior art keywords
compound
reaction
solvent
form vii
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980060128.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN112955449A (zh
Inventor
文峰
陈佳辉
文湘辉
马克·T·埃德加
亨瑞·C·汉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hengyi Biomedical Technology Shanghai Co ltd
Hengyi Biomedicine Shanghai Co ltd
Original Assignee
Hengyi Biomedical Technology Shanghai Co ltd
Hengyi Biomedicine Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hengyi Biomedical Technology Shanghai Co ltd, Hengyi Biomedicine Shanghai Co ltd filed Critical Hengyi Biomedical Technology Shanghai Co ltd
Publication of CN112955449A publication Critical patent/CN112955449A/zh
Application granted granted Critical
Publication of CN112955449B publication Critical patent/CN112955449B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
CN201980060128.8A 2018-09-13 2019-09-13 制备bet溴结构域抑制剂的固体形式的方法 Active CN112955449B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862730849P 2018-09-13 2018-09-13
US62/730,849 2018-09-13
PCT/IB2019/001011 WO2020053657A1 (en) 2018-09-13 2019-09-13 Method of manufacturing a solid form of a bet bromodomain inhibitor

Publications (2)

Publication Number Publication Date
CN112955449A CN112955449A (zh) 2021-06-11
CN112955449B true CN112955449B (zh) 2025-04-29

Family

ID=69777480

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980060128.8A Active CN112955449B (zh) 2018-09-13 2019-09-13 制备bet溴结构域抑制剂的固体形式的方法

Country Status (14)

Country Link
US (2) US12145932B2 (cg-RX-API-DMAC7.html)
EP (2) EP3849980B1 (cg-RX-API-DMAC7.html)
JP (2) JP7731794B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210080373A (cg-RX-API-DMAC7.html)
CN (1) CN112955449B (cg-RX-API-DMAC7.html)
AU (1) AU2019338059B2 (cg-RX-API-DMAC7.html)
CA (1) CA3111527A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190598A1 (cg-RX-API-DMAC7.html)
ES (1) ES3034982T3 (cg-RX-API-DMAC7.html)
IL (1) IL281258B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002885A (cg-RX-API-DMAC7.html)
SG (1) SG11202102497SA (cg-RX-API-DMAC7.html)
TW (1) TWI882964B (cg-RX-API-DMAC7.html)
WO (1) WO2020053657A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI882964B (zh) 2018-09-13 2025-05-11 大陸商恒翼生物醫藥(上海)股份有限公司 Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法
TW202327594A (zh) 2021-09-23 2023-07-16 大陸商恒翼生物醫藥(上海)股份有限公司 用bet溴結構域抑制劑和parp抑制劑的組合治療預選患者群體的三陰性乳腺癌的方法
KR102619331B1 (ko) * 2021-11-30 2023-12-29 주식회사 베노바이오 Bet 단백질을 저해하는 신규한 카르복스아마이드 리독스 유도체 및 이를 이용한 안과질환 예방 및 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105407888A (zh) * 2013-06-21 2016-03-16 齐尼思表观遗传学公司 新双环溴结构域抑制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN105473581B (zh) 2013-06-21 2019-04-23 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新取代的双环化合物
BR122019007990B1 (pt) 2013-11-18 2021-05-04 Forma Therapeutics, Inc Composto, e, composição farmacêutica
CA2966452A1 (en) 2014-12-17 2016-06-23 Samuel David Brown Substituted bicyclic compounds as bromodomain inhibitors
WO2017075377A1 (en) * 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CN109715625B (zh) * 2016-06-20 2022-04-19 因赛特公司 Bet抑制剂的结晶固体形式
WO2018097977A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
TWI816880B (zh) 2018-09-13 2023-10-01 大陸商恒翼生物醫藥(上海)股份有限公司 治療前列腺癌之組合療法
TWI841598B (zh) 2018-09-13 2024-05-11 大陸商恒翼生物醫藥(上海)股份有限公司 用於治療雌激素受體陽性乳癌之組合療法
TWI882964B (zh) 2018-09-13 2025-05-11 大陸商恒翼生物醫藥(上海)股份有限公司 Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105407888A (zh) * 2013-06-21 2016-03-16 齐尼思表观遗传学公司 新双环溴结构域抑制剂

Also Published As

Publication number Publication date
EP4588919A1 (en) 2025-07-23
US20250034142A1 (en) 2025-01-30
EP3849980B1 (en) 2025-04-23
EP3849980A1 (en) 2021-07-21
TW202024078A (zh) 2020-07-01
IL281258B1 (en) 2025-11-01
AU2019338059B2 (en) 2025-03-20
CN112955449A (zh) 2021-06-11
JP2022500433A (ja) 2022-01-04
KR20210080373A (ko) 2021-06-30
WO2020053657A1 (en) 2020-03-19
US20220048905A1 (en) 2022-02-17
IL281258B2 (en) 2026-03-01
CA3111527A1 (en) 2020-03-19
MX2021002885A (es) 2021-07-15
TWI882964B (zh) 2025-05-11
SG11202102497SA (en) 2021-04-29
US12145932B2 (en) 2024-11-19
AU2019338059A1 (en) 2021-04-01
ES3034982T3 (en) 2025-08-27
JP7731794B2 (ja) 2025-09-01
JP2025179092A (ja) 2025-12-09
EA202190598A1 (ru) 2021-08-02
IL281258A (en) 2021-04-29
EP3849980A4 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
AU2018289864B2 (en) Coumarin-like cyclic compound as MEK inhibitor and use thereof
WO2020053660A1 (en) Solid forms of a bet inhibitor
US20250034142A1 (en) Method of manufacturing a solid form of a bet bromodomain inhibitor
CN113024544A (zh) 一种含氰基并杂环化合物及其用途
JP6894917B2 (ja) ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用
WO2011116634A1 (en) Process and intermediates for preparing lapatinib
CN112745335A (zh) 一种三并杂环化合物及其用途
CN111961034A (zh) 用作ret激酶抑制剂的化合物及其应用
CN111825700A (zh) 一种吡嗪并噻唑类化合物、其应用及含其的药物组合物
CN110407877A (zh) 新颖螺环芳基磷氧化物的多晶型
JP2022500433A5 (cg-RX-API-DMAC7.html)
JP7629402B2 (ja) 3-[(1S)-1-イミダゾ[1,2-a]ピリジン-6-イルエチル]-5-(1-メチルピラゾール-4-イル)トリアゾロ[4,5-b]ピラジン及びその多形相の改良製造法
CN103373986A (zh) 克里唑替尼前药及其制备方法与用途
HK40053356A (en) Method of manufacturing a solid form of a bet bromodomain inhibitor
HK40053356B (en) Method of manufacturing a solid form of a bet bromodomain inhibitor
EA043992B1 (ru) Способ изготовления твердой формы ингибитора бромодомена bet
WO2016071382A1 (en) Synthesis of pi3k inhibitor and salts thereof
TW202523285A (zh) 靶向p53突變體的化合物的晶型及其用途
HK40106404A (en) Process for the preparation of benzoxazepin oxazolidinone compounds
CN117836285A (zh) Aurora a选择性抑制剂的多晶型及其用途
JP2025511664A (ja) 4-[5-[ビス(2-クロロエチル)アミノ]-1-メチル-1H-ベンゾ[d]イミダゾール-2-イル]酪酸アルキルエステル及びホルミル化誘導体の調製方法
CN116143754A (zh) 一种琥珀酸曲格列汀杂质化合物的合成方法
HK40037665A (en) Egfr inhibitors
HK1249518B (en) Process of synthesizing substituted pyridine and pyrimidine compound
WO2013089636A1 (en) Processes for manufacturing of a kinase inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40053356

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: 201203 building 10, No. 860, Xinyang Road, Lingang xinpian District, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Applicant after: Hengyi biomedicine (Shanghai) Co.,Ltd.

Address before: Room 413, building 3, 1690 Cailun Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203

Applicant before: Hengyi biomedical technology (Shanghai) Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20391030

TG01 Patent term adjustment